title: Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
abstract: We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin's lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003-12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1-68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).
authors.affiliation: Center for Integrated Oncology, University of Bonn, Bonn, Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Patrij
authors.forename: Marcel
authors.initials: M
authors.lastname: Reiser
authors.forename: Luise
authors.initials: L
authors.lastname: Wätzel
authors.forename: Hendrik
authors.initials: H
authors.lastname: Pels
authors.forename: Annika
authors.initials: A
authors.lastname: Kowoll
authors.forename: Ulrich
authors.initials: U
authors.lastname: Herrlinger
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Michael
authors.initials: M
authors.lastname: Linnebank
authors.forename: Gabriele
authors.initials: G
authors.lastname: Schackert
authors.forename: Marlies
authors.initials: M
authors.lastname: Vogt-Schaden
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Egerer
authors.forename: Monika
authors.initials: M
authors.lastname: Lamprecht
authors.forename: Tracy T
authors.initials: TT
authors.lastname: Batchelor
authors.forename: Uwe
authors.initials: U
authors.lastname: Schlegel
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D053208:Kaplan-Meier Estimate; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000532:radiotherapy; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D003520:Cyclophosphamide; D014751:Vindesine; D007069:Ifosfamide; D008727:Methotrexate